Learning Objectives:

1. Recognize bullous epithelial keratopathy as a rare complication of netarsudil

2. Understand that Descemet stripping endothelial keratoplasty is a viable therapeutic option if the keratopathy does not resolve with cessation of netarsudil

3. Describe the key factors that contribute to prognosis of ocular melanoma

4. Describe treatment modalities available for ocular melanoma and the treatment trials

5. Describe the systemic workup for metastatic uveal melanoma

Session date: 
08/13/2021 - 7:30am to 9:00am CDT
Glenbrook Hospital, Conference Rooms A1-A2
United States
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Please login or create an account to proceed.
Speaker Name: 
Jacob Kanter, MD and Ian Patterson, MD